George W. sledge, Jr., a renowned breast cancer expert and doctor of medicine, will join the Tessa therapeutics board of directors

George W Sledge, Dr Jr is Professor of Stanford University Medical Center and director of oncology department Dr sledge, who brings decades of experience and leadership in cancer research and drug development to Tessa December 24, 2018 / American news agency / -- clinical stage immunotherapy company Tessa, which focuses on developing self and off the shelf allogeneic therapies for cancer patients Therapeutics announced on February 24 that George W sledge, Jr., professor and director of oncology medicine, MD, Stanford University Medical Center, will join Tessa's board of directors as an independent director, which will take effect on January 2, 2019 As the company builds and improves its treatment portfolio to benefit more cancer patients around the world, the appointment is another important step to enhance Tessa's industry expertise Andrew Khoo, co-founder and CEO of Tessa therapeutics, said: "warmly welcome Dr sledge to Tessa's team He brings a wealth of experience, has spent more than 20 years developing new breast cancer biotherapy, and has provided guidance for a phase III study on the use of paclitaxel in the treatment of advanced breast cancer His leadership in cancer research and oncology will provide great support to the board and management team Tessa is really honored to have this outstanding leader join us " Speaking of his new position, Dr sledge said: "I'm very happy to be on the Tessa board Cellular immunotherapy has achieved remarkable results, and I look forward to working with Tessa's entire team to further accelerate the development of this field Tessa's ongoing development of breakthrough immunotherapies and the team's passion and commitment to helping improve the lives of cancer patients around the world are impressive I am looking forward to working with other directors and management to help the company develop more innovative and effective cancer treatment options for patients in need " Dr sledge is co chair of the Scientific Advisory Committee of the Susan g Komen foundation and former president of the American Society for Clinical Oncology (ASCO) He was also a former chair of the breast Committee of the eastern cancer collaboration group (ECoG), a member of the FDA Cancer Drug Advisory Committee, and a member of the National Cancer Institute (NCI) clinical trial Advisory Committee Dr sledge won the 2018 Susan g Komen San Francisco Bay Area visionary Award for his important progress in breast cancer medical research He also won the hope funds for cancer research 2013 "medical excellence" award, the 2010 William L McGuire award from the San Antonio Breast Cancer Seminar and the 2007 Jill rose award from the breast cancer research foundation Tessa therapeutics is an immunotherapy company in the clinical stage, focusing on the development of autogeneic and off the shelf allogeneic therapies for cancer patients Tessa's virus-specific T cell (VST) platform has made remarkable achievements in the treatment of solid tumors by using the strong anti-virus immune response of human body Tessa is building innovative next-generation therapies by combining high-quality VST with other immunooncology technologies Among them, the rapid development of clinical and preclinical autotherapy programs, mainly for nasopharyngeal cancer, cervical cancer, oropharyngeal cancer, liver cancer and lung cancer and other viral and non viral cancer In addition, Tessa also uses its platform to develop allogeneic therapy to treat EBV related lymphoproliferative diseases Tessa has established a sound operation and supply chain capacity, and has successfully provided T-cell therapy for patients all over the world Tessa, together with the company's academic, clinical and commercial research partners, has created a comprehensive programme to tackle cancer with immunotherapy.